Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, USA.
BMT Lab Unit, Clinical Pathology Deptartment, National Cancer Institute, Cairo University, Cairo, Egypt.
Clin Exp Immunol. 2021 Apr;204(1):144-151. doi: 10.1111/cei.13571. Epub 2021 Feb 3.
Behçet disease is a multi-system disease associated with human leukocyte antigen (HLA) class I polymorphism. High-resolution next-generation sequencing (NGS) with haplotype analysis has not been performed previously for this disease. Sixty Egyptian patients diagnosed according to the International Study Group (ISG) criteria for Behçet disease and 160 healthy geographic and ethnic-matched controls were genotyped for HLA class I loci (HLA-A, B, C). For HLA class II loci (DRB1, DRB3/4/5, DQA1, DQB1, DPA1, DPB1), 40 control samples were genotyped. High-resolution HLA genotyping was performed using NGS and the results were analyzed. Clinical manifestations were oral ulcers (100%), genital ulcers (100%), eye (55%) and neurological (28%) and vascular involvement (35%). HLA-B51:08 [odds ratio (OR) = 19·75, 95% confidence interval (CI) = 6·5-79; P < 0·0001], HLA-B15:03 (OR = 12·15, 95% CI = 3·7-50·7; P < 0·0001), HLA-C16:02 (OR = 6·53, 95% CI = 3-14; P < 0·0001), HLA-A68:02 (OR = 3·14, 95% CI = 1·1-8·9; P < 0·01) were found to be associated with Behçet disease, as were HLA-DRB113:01 and HLA-DQB106:03 (OR = 3·39, 95% CI = 0·9-18·9; P = 0·04 for both). By contrast, HLA-A03:01 (OR = 0·13, 95% CI = 0-0·8; P = 0·01) and HLA-DPB117:01 were found to be protective (OR = 0·27, 95% CI = 0·06-1·03; P = 0·02). We identified strong linkage disequilibrium between HLA-B51:08 and C16:02 and A02:01 in a haplotype associated with Behçet disease. HLA-B51:08 was significantly associated with legal blindness (OR = 2·98, 95% CI = 1·06-8·3; P = 0·01). In Egyptian Behçet patients, HLA-B*51:08 is the most common susceptibility allele and holds poor prognosis for eye involvement.
贝切特病是一种与人类白细胞抗原(HLA)I 类多态性相关的多系统疾病。先前尚未对该疾病进行高分辨率下一代测序(NGS)与单体型分析。60 例根据国际研究组(ISG)贝切特病标准诊断的埃及患者和 160 名健康的地理和种族匹配对照者进行了 HLA I 类基因座(HLA-A、B、C)的基因分型。对于 HLA II 类基因座(DRB1、DRB3/4/5、DQA1、DQB1、DPA1、DPB1),对 40 个对照样本进行了基因分型。使用 NGS 进行了高分辨率 HLA 基因分型,并对结果进行了分析。临床表现为口腔溃疡(100%)、生殖器溃疡(100%)、眼部(55%)和神经系统(28%)和血管受累(35%)。HLA-B51:08[比值比(OR)=19.75,95%置信区间(CI)=6.5-79;P<0.0001]、HLA-B15:03(OR=12.15,95%CI=3.7-50.7;P<0.0001)、HLA-C16:02(OR=6.53,95%CI=3-14;P<0.0001)、HLA-A68:02(OR=3.14,95%CI=1.1-8.9;P<0.01)与贝切特病相关,HLA-DRB113:01 和 HLA-DQB106:03 也与贝切特病相关(OR=3.39,95%CI=0.9-18.9;P=0.04)。相比之下,HLA-A03:01(OR=0.13,95%CI=0-0.8;P=0.01)和 HLA-DPB117:01 被发现具有保护作用(OR=0.27,95%CI=0.06-1.03;P=0.02)。我们确定了与 HLA-B51:08 和 C16:02 相关的强连锁不平衡,并在与贝切特病相关的单体型中鉴定出 A02:01。HLA-B51:08 与法律失明显著相关(OR=2.98,95%CI=1.06-8.3;P=0.01)。在埃及的贝切特病患者中,HLA-B*51:08 是最常见的易感等位基因,对眼部受累有不良预后。